(Q37160453)

18 August 2017

1 reference

title

Antipsychotic induced weight gain in schizophrenia:mechanisms and management (English)

1 reference

18 August 2017

1 reference

1 reference

Sanil Rege

1

1 reference

18 August 2017

publication date

1 May 2008

1 reference

Australian and New Zealand Journal of Psychiatry

18 August 2017

published in

1 reference

18 August 2017

volume

42

1 reference

18 August 2017

issue

5

1 reference

18 August 2017

page(s)

369-381

1 reference

The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Use of antipsychotic medications in Australia between July 1995 and December 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Clozapine-induced weight gain predicts improvement in psychopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Association of initial antipsychotic response to clozapine and long-term weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

The metabolic effects of antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Obesity and depression: results from the longitudinal Northern Finland 1966 Birth Cohort Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Obesity, psychiatric status, and psychiatric medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Obesity as a risk factor for antipsychotic noncompliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

The impact of weight gain on quality of life among persons with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Reduced rate of energy expenditure as a risk factor for body-weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Effects of selected serotonin 5-HT(1) and 5-HT(2) receptor agonists on feeding behavior: possible mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Hypothalamic dopamine and serotonin in the regulation of food intake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Weight gain associated with the alpha2a-adrenergic receptor -1,291 C/G polymorphism and olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Psychiatric medication induced obesity: an aetiologic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Genetics of antipsychotic treatment emergent weight gain in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Susceptibility genes for the side effect of antipsychotics on body weight and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Plasma leptin and adiposity during antipsychotic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Effects of long-term treatment with antipsychotics on serum leptin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Antipsychotic-induced weight gain: bipolar disorder and leptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

The physiology of cellular liporegulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Serum ghrelin concentrations in patients receiving olanzapine or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

A prospective study of serum ghrelin levels in patients treated with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Olanzapine increases plasma ghrelin level in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

A clinical study of the association of antipsychotics with hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Association between antipsychotic drugs and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Serum free Fatty acids and glucose metabolism, insulin resistance in schizophrenia with chronic antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Interventions to reduce weight gain in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

The efficacy and safety of sibutramine for weight loss: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Sibutramine and panic attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

The role of endocannabinoid system blockade in the treatment of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Body weight changes associated with psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Metformin for weight loss in pediatric patients taking psychotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Amantadine for weight gain associated with olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Cognitive behavioural therapy for weight gain associated with antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

The Effects of an Educational Intervention on Antipsychotic‐Induced Weight Gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Weight decline in patients switching from olanzapine to quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Reversal of antipsychotic-induced weight gain during quetiapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

A new evidence-based model for weight management in primary care: the Counterweight Programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Metabolic monitoring for patients treated with antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Physical health monitoring of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

What do people with schizophrenia think about weight management?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

Serum leptin levels increase rapidly after initiation of clozapine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670801961123

10.1080/00048670801961123

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference